Dermatology COVID-19 Registries

[1]  S. Feldman,et al.  Learning from disease registries during a pandemic: Moving toward an international federation of patient registries , 2021, Clinics in Dermatology.

[2]  C. Flohr,et al.  Acral Changes in pediatric patients during COVID 19 pandemic: Registry report from the COVID 19 response task force of the society of pediatric dermatology (SPD) and pediatric dermatology research alliance (PeDRA) , 2021, Pediatric dermatology.

[3]  J. Lipoff,et al.  Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases , 2021, Journal of the American Academy of Dermatology.

[4]  R. Grimalt,et al.  A Global eDelphi Exercise to Identify Core Domains and Domain Items for the Development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS). , 2021, JAMA dermatology.

[5]  J. Lipoff,et al.  Cold and COVID: recurrent pernio during the COVID‐19 pandemic , 2021, The British journal of dermatology.

[6]  J. Lipoff,et al.  Long COVID in the skin: a registry analysis of COVID-19 dermatological duration , 2021, The Lancet Infectious Diseases.

[7]  D. Tobin,et al.  Shedding light on therapeutics in alopecia and their relevance to COVID-19 , 2020, Clinics in Dermatology.

[8]  R. Trüeb,et al.  What can the hair tell us about COVID‐19? , 2020, Experimental dermatology.

[9]  R. Grimalt,et al.  SARS‐CoV‐2‐induced telogen effluvium: a multicentric study , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  L. Naldi,et al.  Risk‐mitigating behaviours in people with inflammatory skin and joint disease during the COVID‐19 pandemic differ by treatment type: a cross‐sectional patient survey* , 2020, medRxiv.

[11]  S. Feldman,et al.  Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study , 2020, Journal of Allergy and Clinical Immunology.

[12]  M. Lebwohl,et al.  National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1 , 2020, Journal of the American Academy of Dermatology.

[13]  M. Shanshal,et al.  COVID-19 related anagen effluvium , 2020, The Journal of dermatological treatment.

[14]  J. Lipoff,et al.  Timing of PCR and antibody testing in patients with COVID-19–associated dermatologic manifestations , 2020, Journal of the American Academy of Dermatology.

[15]  M. Lowes,et al.  Global Hidradenitis Suppurativa COVID‐19 Registry: a registry to inform data‐driven management practices , 2020, The British journal of dermatology.

[16]  S. Feldman,et al.  International collaboration and rapid harmonization across dermatologic COVID-19 registries , 2020, Journal of the American Academy of Dermatology.

[17]  J. Lipoff,et al.  Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries , 2020, Journal of the American Academy of Dermatology.

[18]  J. Lipoff,et al.  The spectrum of COVID-19–associated dermatologic manifestations: An international registry of 716 patients from 31 countries , 2020, Journal of the American Academy of Dermatology.

[19]  E. Freeman,et al.  The American Academy of Dermatology COVID-19 registry: Crowdsourcing dermatology in the age of COVID-19 , 2020, Journal of the American Academy of Dermatology.

[20]  R. Trimble.  COVID-19 Dashboard , 2020 .

[21]  R. Grimalt,et al.  The Alopecia Areata Consensus of Experts (ACE) Study: Results of an International Expert Opinion on Treatments for Alopecia Areata. , 2020, Journal of the American Academy of Dermatology.